期刊文献+

血府逐瘀口服液治疗冠心病心绞痛临床观察 被引量:3

Clinical Observation on Effect of Xuefuzhuyu Oral Solution on Coronary Heart Disease with Angina Pectoris
下载PDF
导出
摘要 目的观察血府逐瘀口服液治疗冠心病心绞痛的临床疗效。方法选择冠心病心绞痛患者80例,随机单盲分为两组,血府逐瘀口服液组和西药对照组各40例,分别予以血府逐瘀口服液和西药消心痛、阿司匹林对照治疗四周。结果血府逐瘀口服液组、西药对照组总有效率分别为92.5%和75%;心电图疗效,血府逐瘀口服液组、西药对照组有效率分别为66%和40%,两组比较差异均有显著性(P﹤0.05);血府逐瘀口服液组治疗后血胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)明显降低(P﹤0.05,P﹤0.01),西药对照组LDL-C则有所升高(P﹤0.05)。结论血府逐瘀口服液对冠心病心绞痛在改善心绞痛症状、缺血心电图改变等方面有较好疗效,同时还可降低TC及LDL-C,降低动脉硬化指数。 Objective To observe the effect of Xuefuzhuyu Oral Solution(XFOS) in treating coronary heart disease with angina pectoris. Methods Eighty patients were randomly divided into two groups. They were treated with XFOS group and isosorbide dinitrate combined aspirin(control group) respectively for 4 weeks and observed by single blind method. Results The total effective rate in relieving angina in the XFOS group and the control group was 92.5% and 75% respectively , that in improving ECG changes was 65% and 40% respectively, the difference of the two parameters between the two groups was significant, all P<0.05.Levels of total cholesterol(TC) and low density lipoprotein-cholesterol(LDL-C)were lowered in the XFOS group while LDL-C was increased in the control group. Conclusion XLOS has better effect in improving angina pectoris, ischemic changes in ECG, it could also reduce the serum TC and LDL-C level and decrease the arteriosclerosis index.
作者 廖周华 梁岩
出处 《中国医药导报》 CAS 2006年第5期17-18,共2页 China Medical Herald
关键词 血府逐瘀口服液 冠心病心绞痛 血脂 Xuefuzhuyu Oral Solution coronary heart disease with angina pectoris blood lipid
  • 相关文献

参考文献6

二级参考文献13

  • 1杨人勋,徐伟,李祖兴.脂蛋白(a)与动脉粥样硬化[J].心血管病学进展,1994,15(4):221-224. 被引量:18
  • 2吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3):162-164. 被引量:231
  • 3赵三妹,中华病理学杂志,1987年,16卷,4期,260页
  • 4刘西苹,福建中医药,1988年,19卷,58页
  • 5Norman M Kaplan,冠心病的预防,1990年,183页
  • 6匿名著者,中西医结合杂志,1987年,7卷,3期,129页
  • 7蔡海江,动脉粥样硬化与冠心病,1982年,50页
  • 8王阶,活血化瘀研究与临床,1993年,7页
  • 9武继彪,国外医学.药学分册,1990年,17卷,5期,276页
  • 10Hong M K,Current Problem Cardiology,1997年,22卷,1期,736页

共引文献214

同被引文献61

  • 1陈隽妍,毛威,倪桂宝,李剑钢.动脉粥样硬化痰瘀互结证大鼠模型的建立[J].现代中西医结合杂志,2007,16(26):3789-3793. 被引量:9
  • 2李静,陈可冀,张靖溥,丁大成.血管通对实验性动脉粥样硬化家兔血管壁血小板衍化生长因子A、B及c-myc基因表达的影响[J].中国中西医结合杂志,1995,15(1):33-35. 被引量:89
  • 3高耀宗.加味当归补血汤治疗冠心病心绞痛[J].中西医结合心脑血管病杂志,2005,3(12):1120-1120. 被引量:10
  • 4Calabro P, Samudio I,Willerson JT. Resistin pro-motes smooth muscle cell proliferation throughactivation of extracellular signal-regulated kinase1/2 and phosphatidylinositol 3-kinase pathways[J]. Circulation, 2004, 110(21) : 3335 -3340.
  • 5Gotto AM. Evolving concepts of dyslipidemia, ath-erosclerosis and cardiovascular disease: theLouis F. Bishop Lecture [ J ]. J Am Coll Cardiol,2005,46(7) : 1219 -1224.
  • 6Hoch RV,Soriano P. Roles of PDGF in animal de-velopment [ J ]. Development, 2003,130 (20):4769 -4784.
  • 7Matsui T,Rosenzweig A. Convergent signaltransduction pathways controlling cardiomyocytesurvival and function: the role of PI3-kinase andAkt[J]. J Mol Cell Cardiol, 2005,38(1) : 63 -71.
  • 8Chang MW, Barr E, Seltzer J, et at. Cytostaticgene therapy for vascular proliferative disorderswith a constitutively active form of the retinoblas-toma gene product [ J ]. Science, 1995,267(5197); 518 -522.
  • 9Crowley ST, Ray CJ, Nawaz D, et al. Multiplegrowth factors are released from mechanically in-jured vascular smooth muscle cells [ J ]. Am JPhysiol, 1995,269(5 Pt2): 1641 -1647.
  • 10Me Cubrey JA,Steelman LS, Chappell WH,et al.Roles of the Raf/MEK/ERK pathway in cellgrowth, malignant,transformation and drug re-sistance[ J ]. Biochim Biophys Acta, 2007,1773(8): 1263 -1284.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部